BrightInsight and BioMerix announce partnership to launch medical digital options for diagnostics

BioMérieux’s resolution goals to enhance medical workflow and ship actionable information to cross-functional care groups

San Jose, California and Salt Lake Metropolis, September 21, 2022 (Globe Newswire) — BrightInsight, Inc.Supplier of the main international platform for Biopharma and MedTech regulated digital well being options and BIOMERIEUXA world chief within the discipline of in vitro diagnostics, right now introduced a partnership to develop and market medical digital options for diagnostics that help medical choice help for illness areas of their diagnostic assessments. make succesful.

As healthcare suppliers are charged with delivering higher affected person outcomes at a decrease complete price of care, it will be significant that physicians reap the benefits of the insights offered by excessive worth prognosis in a well timed, optimum method. To deal with this healthcare want, BioMerix will launch a digital resolution for diagnostics leveraging the compliant BrightInsight® platform and BrightInsight Illness Administration Resolution; Know-how that may be configured to satisfy the very best regulated Digital Well being Software program as Medical Gadget (SAMD) classification. This resolution will enhance medical workflow, contextualize illness consciousness, and in the end allow a extra holistic affected person strategy to assist clinicians make actionable, knowledgeable selections. BioMérieux’s medical digital resolution will launch within the US first, with a deliberate international enlargement.

“We have now discovered a associate at BrightInsight who shares our dedication to advancing public well being with revolutionary, customer-focused options. Our affiliation with BrightInsight will allow us to quickly carry our digital well being options to market with the objective of enhancing affected person outcomes,” stated Brian Armstrong, Senior Vice President, Medical Operations – North America.

“We’re honored to associate with BioMerix to help the event of medical digital options, together with medical choice help instruments utilized in ICUs, to evaluate threat and Assist cut back the incidence of preventable illnesses,” stated Kal Patel, MD, CEO and co-founder, BrightInsight. “BioMerix is ​​a acknowledged in vitro diagnostics chief, becoming a member of a stellar group of life science firms which might be leveraging our confirmed, compliant BrightInsight platform to put the inspiration for his or her transformational SaMD and digital well being options.”

“As a worldwide group, we want a associate with a worldwide footprint and platform,” stated Mark Bonet, senior vp of World Well being Information Insights at BioMerix. “BrightInsight’s illness administration options are scalable and configurable to the regulatory, privateness and safety wants of a myriad of well being markets. We stay up for working with BrightInsight to carry revolutionary and important digital options to market.”

BrightInsight, Inc. about
BrightInsight gives the main international platform for biopharma and medtech regulated digital well being options. When velocity issues, we help firms for regulated digital well being choices within the therapeutic areas, together with apps, healthcare supplier interfaces, analytics dashboards, algorithms, medical gadgets, linked mixture merchandise, diagnostics and software program as a medical system (SAMD). Helps to speed up the market. BrightInsight replaces the necessity for prolonged and complicated ‘construct from scratch’ implementations by providing configurable software program options on Google Cloud and a confirmed platform beneath a top quality administration system to help international safety, privateness and regulatory necessities. When constructing digital well being merchandise on the BrightInsight platform, compliance is future-proofed as meant use change scales throughout all geographies.

For extra info, go to BrightInsight’s . go to Web site, weblog, TwitterAnd linkedin Web page.

About Biomarix

main prognosis

A world chief in in vitro diagnostics since 1963, Biomerix is ​​current in 45 nations and serves over 160 nations with the help of a big community of distributors. In 2021, income reached 3.4 billion euros, with greater than 90% of gross sales exterior France.

BioMérieux gives diagnostic options (programs, reagents, software program and companies) that decide the supply of illness and contamination to enhance affected person well being and guarantee shopper security. Its merchandise are primarily used for the prognosis of infectious illnesses. They’re additionally used to detect microorganisms
Agri-food, pharmaceutical and beauty merchandise.

Biomerix is ​​listed on the Euronext Paris inventory alternate.
Image: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP

media and press
Jamie Burgess
SVP, Advertising, BrightInsight

Helen Shiko
Brightinsight PR Agency
Schick Communications LLC

liza dekelbaum
BioMerix PR Contact

Copyright © 2022 BrightInsight, Inc. BrightInsight and the BrightInsight emblem BrightInsight, Inc. are emblems of. Different emblems are emblems of their homeowners.

A photograph accompanying this announcement is out there at

primary logo

BIM Graphic

BioMérieux is listed on the Euronext Paris inventory alternate. Image: BIM – ISIN code: FR0013280286 Reuters: BIOX.PA/Bloomberg: BIM.FP

Supply hyperlink